Furthermore, in EVs isolated from patients with prostate cancer, higher levels of CD81 and prostate-specific antigen (PSA) were detected, which could discriminate prostate cancer patients from benign prostatic hyperplasia and healthy individuals [155]. This evidence concerns the gene CD81 and prostate carcinoma.